A blood test for Alzheimer’s disease is now available for clinical use in persons with cognitive impairment. This is an extraordinary milestone, though the amyloid-based PrecivityAD™ test is not without limitations. Pre and post-test counseling are essential. Phosphorylated tau blood tests are likely to follow soon. When used in conjunction with an appropriate clinical evaluation, blood tests provide the opportunity for an early, accurate, and accessible diagnosis of Alzheimer’s disease. Standalone use, however, carries a significant risk of misinterpretation and is strongly discouraged. Now is the time to develop appropriate use criteria to guide the use of these promising assays.
Lesman-SegevOH, La JoieR, IaccarinoL, LobachI, RosenHJ, SeoSW, JanabiM, BakerSL, EdwardsL, PhamJ, OlichneyJ, BoxerA, HuangE, Gorno-TempiniM, DeCarliC, HepkerM, HwangJL, MillerBL, SpinaS, GrinbergLT, SeeleyWW, JagustWJ, RabinoviciGD (2021) Diagnostic accuracy of amyloid versus 18 F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia. Ann Neurol89, 389–401.
3.
HanssonO, LehmannS, OttoM, ZetterbergH, LewczukP (2019) Advantages and disadvantages of the use of the CSF amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s disease. Alzheimers Res Ther11, 34.
4.
RabinoviciGD, GatsonisC, ApgarC, ChaudharyK, GareenI, HannaL, HendrixJ, HillnerBE, OlsonC, Lesman-SegevOH, RomanoffJ, SiegelBA, WhitmerRA, CarrilloMC (2019) Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA321, 1286–1294.
5.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFR, VisserPJ; Amyloid Biomarker Study Group, AaltenP, AarslandD, AlcoleaD, AlexanderM, AlmdahlIS, ArnoldSE, BaldeirasI, BarthelH, van BerckelBN, BibeauK, BlennowK, BrooksDJ, van BuchemMA, CamusV, CavedoE, ChenK, ChetelatG, CohenAD, DrzezgaA, EngelborghsS, FaganAM, FladbyT, FleisherAS, van der FlierWM, FordL, FörsterS, ForteaJ, FoskettN, FrederiksenKS, Freund-LeviY, FrisoniGB, FroelichL, GabryelewiczT, GillKD, GkatzimaO, Gómez-TortosaE, GordonMF, GrimmerT, HampelH, HausnerL, HellwigS, HerukkaSK, HildebrandtH, IshiharaL, IvanoiuA, JagustWJ, JohannsenP, KandimallaR, KapakiE, Klimkowicz-MrowiecA, KlunkWE, KöhlerS, KoglinN, KornhuberJ, KrambergerMG, Van LaereK, LandauSM, LeeDY, de LeonM, LisettiV, LleóA, MadsenK, MaierW, MarcussonJ, MattssonN, de MendonçaA, MeulenbroekO, MeyerPT, MintunMA, MokV, MolinuevoJL, MøllergårdHM, MorrisJC, MroczkoB, Van der MusseleS, NaDL, NewbergA, NordbergA, NordlundA, NovakGP, ParaskevasGP, ParnettiL, PereraG, PetersO, PoppJ, PrabhakarS, RabinoviciGD, RamakersIH, RamiL, Resende de OliveiraC, RinneJO, RodrigueKM, Rodríguez-RodríguezE, RoeCM, RotU, RoweCC, RütherE, SabriO, Sanchez-JuanP, SantanaI, SarazinM, SchröderJ, SchütteC, SeoSW, SoeteweyF, SoininenH, SpiruL, StruyfsH, TeunissenCE, TsolakiM, VandenbergheR, VerbeekMM, VillemagneVL, VosSJ, van Waalwijk van DoornLJ, WaldemarG, WallinA, WallinÅK, WiltfangJ, WolkDA, ZbochM, ZetterbergH (2015) Prevalence of cerebralamyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
6.
KapasiA, DeCarliC, SchneiderJA (2017) Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol134, 171–186.
7.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, CarrilloMC, HartleyDM, HedrickS, PappasV, ThiesWH (2013) Appropriate use criteria for amyloid PET: A reportof the Amyloid Imaging Task Force, the Society of Nuclear Medicine and MolecularImaging, and the Alzheimer’s Association. J Nucl Med54, 476–490.
8.
ShawLM, AriasJ, BlennowK, GalaskoD, MolinuevoJL, SallowayS, SchindlerS, CarrilloMC, HendrixJA, RossA, IllesJ, RamusC, FiferS (2018) Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. Alzheimers Dement14, 1505–1521.
9.
van MaurikIS, Rhodius-MeesterHFM, TeunissenCE, ScheltensP, BarkhofF, PalmqvistS, HanssonO, van der FlierWM, BerkhofJ (2021) Biomarker testing in MCI patients-deciding who to test. Alzheimers Res Ther13, 14.
10.
FrederiksenKS, NielsenTR, WinbladB, SchmidtR, KrambergerMG, JonesRW, HortJ, GrimmerT, GeorgesJ, FrölichL, EngelborghsS, DuboisB, WaldemarG (2021) . European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. Eur J Neurol28, 2147–2155.
11.
Lantero RodriguezJ, KarikariTK, Suárez-CalvetM, TroakesC, KingA, EmersicA, AarslandD, HyeA, ZetterbergH, BlennowK, AshtonNJ (2020) Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol140, 267–278.
12.
PalmqvistS, JanelidzeS, QuirozYT, ZetterbergH, LoperaF, StomrudE, SuY, ChenY, SerranoGE, LeuzyA, Mattsson-CarlgrenN, StrandbergO, SmithR, VillegasA, Sepulveda-FallaD, ChaiX, ProctorNK, BeachTG, BlennowK, DageJL, ReimanEM, HanssonO (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA324, 772–781.
13.
AshtonNJ, PascoalTA, KarikariTK, BenedetAL, Lantero-RodriguezJ, BrinkmalmG, SnellmanA, SchöllM, TroakesC, HyeA, GauthierS, VanmechelenE, ZetterbergH, Rosa-NetoP, BlennowK (2021) Plasma p-tau231: A new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol141, 709–724.
14.
SyrjanenJA, CampbellMR, Algeciras-SchimnichA, VemuriP, Graff-RadfordJ, MachuldaMM, BuG, KnopmanDS, JackCRJr, PetersenRC, MielkeMM (2021) Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. doi: 10.1002/alz.12466
15.
CullenNC, LeuzyA, PalmqvistS, JanelidzeS, StomrudE, PesiniP, SarasaL, AlluéJA, ProctorNK, ZetterbergH, DageJL, BlennowK, Mattsson-CarlgrenN, HanssonO (2021) Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations . Nat Aging1, 114–123.
16.
WestT, KirmessKM, MeyerMR, HolubaschMS, KnapikSS, HuY, ContoisJH, JacksonEN, HarpstriteSE, BatemanRJ, HoltzmanDM, VerghesePB, FogelmanI, BraunsteinJB, YarasheskiKE (2021) A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: Findings from a multi cohort validity analysis. Mol Neurodegener16, 30.
